Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HQK-1001 in Sickle Cell Disease
NCT01601340Phase 2Terminated
- Sponsor
- HemaQuest Pharmaceuticals, Inc.
- Start
- Jul 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of sodium 2,2-dimethylbutyrate in sickle cell disease (SCD), sponsored by HemaQuest Pharmaceuticals, Inc.. Started Jul 2012; status: terminated.
02
Drugs
sodium 2,2-dimethylbutyrate
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT01601340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01601340.